DexCom receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DexCom Inc (DXCM)
The DexCom share price today is 70.26, view NASDAQ DXCM stock exchange data. Track the latest DexCom share price with real-time updates on DXCM stock performance including market cap, day range, 52-week range and dividend yield. Access DXCM charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
69.92
72.65
52 wk Range
54.11
89.98
DXCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
69.9272.65
52 wk Range
54.1189.98
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DXCM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
81.84
Upside
+16.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Management has been aggressively buying back shares
- DexCom receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 DEXCOM For: 21 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
24 Buy
3 Hold
1 Sell
Ratings:
28 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 81.84
(+16.48% Upside)
DexCom Inc SWOT Analysis
Diabetes Tech Leade | DexCom dominates the continuous glucose monitoring market with strong sales growth and record new patient starts, despite facing recent margin pressures from supply chain challenges. |
Growth Catalysts | Expansion into the Type 2 diabetes market and the upcoming G7 15-day sensor launch present significant opportunities, with 6 million new covered lives expected by year-end 2025. |
Financial Headwinds | Despite robust sales of $1.04 billion in Q1 2025, DexCom faces margin challenges from quality initiatives and supply issues, prompting revised forecasts for 2026. |
Analyst Outlook | Price targets range from $80 to $102, averaging $91.25, reflecting mixed sentiment as DexCom balances market leadership against competitive threats from Abbott and potential regulatory hurdles. |
DexCom Inc Earnings Call Summary for Q1/2026
- DexCom Q1 2026 EPS of $0.56 beat estimates by 19%; revenue of $1.19B exceeded forecasts by 1.71%, driving 3.41% stock gain to $57.99.
- Revenue rose 15% YoY with international sales surging 26% to $360M; U.S. sales increased 11% to $832M on strong CGM system demand.
- Gross margin expanded to 63.5% from 57.5% YoY; operating income jumped to 22.2% of revenue vs. 13.8% in Q1 2025.
- Company raised FY2026 operating margin guidance to 23%-23.5% and EBITDA margin to 31%-31.5%; expects revenue of $5.16B-$5.25B.
- CEO cited sustainable growth and margin expansion; risks include geopolitical cost pressures, competition, and potential supply chain disruptions.
Last Updated: 01-05-2026, 03:26 am
Read Full TranscriptEarnings
Latest Release
30-04-2026
EPS / Forecast
0.56 / 0.47
Revenue / Forecast
1.19B / 1.17B
Compare DXCM to Peers and Sector
Metrics to compare | DXCM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDXCMPeersSector | |
|---|---|---|---|---|
P/E Ratio | 29.1x | 20.1x | −0.5x | |
PEG Ratio | 0.39 | −0.56 | 0.00 | |
Price/Book | 9.2x | 3.3x | 2.6x | |
Price / LTM Sales | 5.6x | 2.6x | 3.1x | |
Upside (Analyst Target) | 13.9% | 66.6% | 54.9% | |
Fair Value Upside | Unlock | 6.8% | 7.1% | Unlock |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the DexCom (DXCM) Share Price Today?
The DexCom share price today is 70.26.
What is the current DexCom (DXCM) share price and day range?
As of 28-05-2026, the DexCom share price is 70.26, with a previous close of 70.26. The share price has ranged from 69.92 to 72.65 today, while the 52-week range spans from 54.11 to 89.98.
What Is the DexCom Market Cap?
As of today, DexCom market cap is 27.11B.
What Is the DexCom (DXCM) Share Price Target?
The average 12-month share price target for DexCom is 81.84, with a high estimate of 112 and a low estimate of 64. 24 analysts recommend buying, while 1 suggest selling, with an overall rating of Strong Buy and +16.48% Upside potential.
What Is DexCom's Earnings Per Share (TTM)?
The DexCom EPS (TTM) is 2.34.
When Is the Next DexCom Earnings Date?
DexCom will release its next earnings report on 23-07-2026.
From a Technical Analysis Perspective, Is DXCM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does DexCom Trade On?
DexCom is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for DexCom?
The stock symbol for DexCom is "DXCM."
How Many Times Has DexCom Stock Split?
DexCom has split 1 times.
How Many Employees Does DexCom Have?
DexCom has 11050 employees.
What Is the DXCM Premarket Price?
DXCM's last pre-market stock price is 70.05. The pre-market share volume is 3,290.00, and the stock has changed by -0.21, or -0.30%.
What Is the DXCM After Hours Price?
DXCM's last after hours stock price is 70.27, the stock has changed by 0.01, or 0.01%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.